Crizanlizumab, an anti–P-selectin antibody, reduces the frequency of painful events [130] and biomarkers of P-selectin–mediated adhesion correlate with patient-reported pain in the Evaluation of Longitudinal Pain Study in Sickle Cell Disease study [131]. The gene discussed is SELP; the disease is sickle cell disease.